Phytochemical studies on the liverwort Radula genus have previously identified the bibenzyl (−)-cis-perrottetinene (cis-PET), which structurally resembles (−)-Δ9-trans-tetrahydrocannabinol (Δ9-trans-THC) from Cannabis sativa L. Radula preparations are sold as cannabinoid-like legal high on the internet, even though pharmacological data are lacking. Herein, we describe a versatile total synthesis of (−)-cis-PET and its (−)-trans diastereoisomer and demonstrate that both molecules readily penetrate the brain and induce hypothermia, catalepsy, hypolocomotion, and analgesia in a CB1 receptor–dependent manner in mice. The natural product (−)-cis-PET was profiled on major brain receptors, showing a selective cannabinoid pharmacology. This study also uncovers pharmacological differences between Δ9-THC and PET diastereoisomers. Most notably, (−)-cis-PET and (−)-trans-PET significantly reduced basal brain prostaglandin levels associated with Δ9-trans-THC side effects in a CB1 receptor–dependent manner, thus mimicking the action of the endocannabinoid 2-arachidonoyl glycerol. Therefore, the natural product (−)-cis-PET is a psychoactive cannabinoid from bryophytes, illustrating the existence of convergent evolution of bioactive cannabinoids in the plant kingdom. Our findings may have implications for bioprospecting and drug discovery and provide a molecular rationale for the reported effects upon consumption of certain Radula preparations as moderately active legal highs.
Cannabinoids have a wide range of actual and potential therapeutic applications, and marijuana is widely used not only for its recreational but also for its medicinal properties (1, 2). To date, the plant Cannabis sativa L. is the only known natural source of CB1 cannabinoid receptor (CB1R) activators, with Δ9-trans-tetrahydrocannabinol (Δ9-trans-THC) being the most potent partial agonist (3, 4). The THC scaffold was presumed unique to the Cannabis plant genus until the bibenzyl cis-THC, (−)-cis-perrottetinene (cis-PET) (Fig. 1), was isolated from the liverwort Radula perrottetii Gottsche ex Steph in 1994 by Asakawa and co-workers and later from Radula marginata Taylor ex Gottsch (5, 6). Further, Cullman and Becker isolated cis-PET from Radula laxiramea Steph (7). Bryophytes are a distinctive group of an early-diverged lineage of nonvascular land plants comprising more than 20,000 species (Fig. 1). This division includes mosses, hornworts, and liverworts (8). Liverworts often generate the opposite stereochemical configuration in secondary metabolite biosynthesis compared with higher plants (9). This is also the case for the cis configuration in the cyclohexene ring in cis-PET compared with Δ9-trans-THC. The absolute stereochemistry of cis-PET was fully structurally characterized in 2008 (10). Comparatively little attention has been paid to the liverworts for use in human diet or medicine to date (9). Worldwide anecdotal reports both affirm and refute the effectiveness of consuming R. marginata preparations inducing a legal cannabis-like high. However, the pharmacology of this natural product remains unknown. R. marginata is endemic to New Zealand and Tasmania, and collected dried samples are currently sold via the internet as an emerging recreational drug or as incense (see Acknowledgments). A molecular understanding of the effects of PET is essential to anticipate potential toxicological or recreational effects in humans. On the basis of a previously established stereodivergent synthesis of Δ9-THCs (11–13), we report a versatile total synthesis of natural cis-PET and its (−)-trans diastereoisomer (Figs. 2 and 3). This enabled a comparative study of PET and Δ9-THC structure-activity relationships for CB1R and CB2R activation, respectively, as well as cannabimimetic and biochemical effects in mice. To further investigate the pharmacological effects of the liverwort cannabinoid, we measured the bioavailability of cis-PET to the brain and profiled this natural product on major central nervous system (CNS) receptors. The CB1R-mediated psychoactive pharmacology is characterized by a typical central effect pattern in mice, generally referred to as the “tetrad test,” which includes antinociception, hypothermia, catalepsy, and locomotion inhibition (14). A full assessment of both PET diastereoisomers on the endocannabinoid system (ECS) was performed. This study not only provides a molecular basis on which to assess the mode of action and emerging recreational use of smoked Radula liverwort preparations as legal high but also allows a direct comparison with Δ9-THC for potential therapeutic applications.
At the human cannabinoid receptor type 1 (CB1R), the natural product cis-PET exhibited a Ki = 481 nM, while its diastereoisomer trans-PET was more potent (Ki = 127 nM) (see Table 1 and fig. S1). Similarly, at the human peripheral cannabinoid receptor type 2 (CB2R), Ki values of 225 and 126 nM for cis- and trans-PET were measured, respectively. These differences parallel the lower affinity of Δ9-cis-THC compared to Δ9-trans-THC. Δ9-cis-THC is a minor cannabinoid in cannabis (16) and a moderately active CB1R partial agonist (Table 1), in agreement with the in vivo data reported for racemic Δ9-cis-THC prior to the identification of CB receptors (17). Thus, the benzyl substituent in PET does not fundamentally alter the binding relationships at CB receptors. In [35S]GTPγS binding assays, both PETs were partial CB1R agonists such as the Δ9-THCs, reaching 60 to 80% of the maximal efficacy of the known full CB1R/CB2R agonist CP55,940 (see Table 1 and fig. S2). At the CB1R functional level, cis-PET was about 10 times less potent than Δ9-trans-THC [half maximal effective concentration (EC50) = 406 nM versus 43 nM] (fig. S2A). Similarly, Δ9-trans-THC showed a lower EC50 value at CB2R compared with cis-PET (12 nM versus 167 nM) (fig. S2B). cis-PET was slightly more potent at CB2R than trans-PET, revealing a distinct stereochemical bias toward CB2R over CB1R at the functional level as compared with the corresponding Δ9-THCs. At CB2R, all cannabinoids were inefficient partial agonists despite their nanomolar receptor binding affinities. No relevant effects on the major endocannabinoid-degrading enzymes fatty acid amid hydrolase (FAAH), monoacyl glycerol lipase (MAGL), and α/β hydrolases 6 and 12 (ABHD6 and ABHD12) were observed in vitro below 10 μM (table S1).
View this table:
We developed a liquid chromatography–tandem mass spectrometry (LC-MS/MS) method to quantify Δ9-trans-THC, cis-PET, and trans-PET in the brain. Endocannabinoid levels and other N-acetylethanolamines (NAEs), arachidonic acid (AA), prostaglandin D2 (PGD2), and prostaglandin E2 (PGE2) were quantified to evaluate potential biochemical changes upon cannabinoid exposure (Fig. 5 and fig. S3). We measured Δ9-trans-THC, cis-PET, and trans-PET concentrations of 0.24, 1.64, and 0.80 nmol/g, respectively, in total brain 1 hour after injection (Fig. 5A). This corresponds to a concentration of 197 nM for Δ9-trans-THC, 1350 nM for cis-PET, and 662 nM for trans-PET, in line with the bioactive concentrations for CB1R activation (Table 1). Correlation between brain penetration and behavioral pharmacology was also observed for Δ9-trans-THC (Fig. 5A), in line with the literature (18). In plasma, the concentrations of Δ9-trans-THC, cis-PET, and trans-PET were 0.47, 1.79, and 1.56 nmol/ml, respectively (fig. S4). These results show that Δ9-trans-THC and PET diastereoisomers rapidly and efficiently accumulate in the brain with Cbrain/Cplasma ratios (Kp values) of 0.51 for Δ9-trans-THC, 0.91 for cis-PET, and 0.51 for trans-PET. Animals treated with Δ9-trans-THC, cis-PET, and trans-PET did not display any significant modulation of the endocannabinoids anandamide (AEA) and 2-arachidonoyl glycerol (2-AG) levels in the brain as compared with vehicle (Fig. 5, B and C). Similarly, the brain levels of AA were not affected by the treatments (Fig. 5D). Unexpectedly, cis- and trans-PET significantly reduced the basal levels of PGD2 and PGE2 in the brain in a CB1 receptor–dependent manner (Fig. 5, E and F). In sharp contrast, no significant acute effects on prostaglandins were observed in Δ9-trans-THC–treated animals. Given the wide-reaching importance of prostaglandins in the brain (19, 20), these pharmacological effects notably differentiate PET from Δ9-trans-THC.
To characterize the in vitro pharmacology of cis-PET, we assessed this novel cannabinoid in a screening panel of 44 CNS targets, including G protein–coupled receptors (GPCRs), ion channels, nuclear receptors, membrane transporters, and enzymes. At the concentration of 10 μM (blue line), cis-PET showed the highest binding affinity toward CB1R and CB2R (≥90%), followed by serotonin receptors 5-HT2A (86%) and 5-HT2B (85%), cholecystokinin receptor (CCK1; 84%), dopamine transporter (DAT; 83%), and l-type Ca2+ channel (80%) (Fig. 6). At a concentration of 1 μM, cis-PET still binds significantly to CB1R (68%) and CB2R (75%), while it markedly lost affinity for 5-HT2A (5%), 5-HT2B (30%), CCK1 (32%), DAT (27%), and l-type Ca2+ channel (9%) (Fig. 6, orange line). This is in agreement with the full CB1R dependence of the cis-PET effects in vivo obtained in the behavioral tests (Fig. 4, tetrad) and modulation of prostaglandin levels in mouse brain (Fig. 5, E and F). Last, these data are also in perfect agreement with the measured brain concentration of cis-PET, which reached approximately 1.4 μM at the dose of 50 mg/kg (Fig. 5A). Δ9-trans-THC has been shown to interact with other targets beyond CB receptors at concentrations between 1 and 10 μM, including 5-HT2A receptors, DAT, Ca2+ channels, Na+ channels, Kv channels, and monoamino oxidase (MAO) (21–23). In addition, Δ9-trans-THC inhibited 5-HT transporter (SERT) and norepinephrine transporter (NAT) at concentrations <1 μM (21, 22). To directly compare cis-PET and Δ9-trans-THC, the latter was also assessed in the screening panel of 44 CNS targets at 1 μM (Fig. 6). The results indicate specific binding to CB1R (95%) and CB2R (90%), with only minor effects on CCK1 (40%), DAT (22%), and histamine 1 receptor (H1; 20%). Neither Δ9-trans-THC nor cis-PET inhibited cyclooxygenase-2 (COX-2) at physiological concentrations (Fig. 6 and fig. S5).
The isolation of the liverwort-derived bibenzyl cannabinoid cis-PET was first reported in 1994 (5), although in 1988, Crombie and co-workers already predicted cis-PET as a natural product (24). Possibly because of a lack of isolated pure substance, no research was conducted on its biological activity. In recent years, reports on Radula as legal high have accumulated. Our study shows that cis-PET is a moderately potent but efficacious psychoactive cannabinoid identified outside the Cannabis genus, in agreement with the reported recreational use of R. marginata, which is endemic to New Zealand and Tasmania. Like Δ9-trans-THC, cis-PET occurs in the plant as acid (5, 6), which is progressively decarboxylated upon drying or smoking. Dried R. marginata collected in the wild is currently sold in the internet as legal high, making reference to cis-PET being structurally similar to THC (see Acknowledgments). The online community reporting about legal highs both affirms and refutes the anecdotes regarding the cannabis-like effects of smoked R. marginata. Given the uncertain amounts of cis-PET in the purchasable preparations and the lack of information regarding the pharmacology of cis-PET, we synthesized both PET diastereoisomers and tested them in vitro and in mice. We show that cis-PET is readily bioavailable to the brain in mice (Kp value of 0.91) and selectively binds to CB1 and CB2 cannabinoid receptors CB1R and CB2R at nanomolar concentrations in vitro, without affecting the other components of the ECS and 44 CNS targets including GPCRs, ion channels, nuclear receptors, membrane transporters, and enzymes. In vivo, cis-PET induced analgesia, catalepsy, hypolocomotion, and hypothermia (collectively called tetrad) in a CB1R-dependent manner similarly to Δ9-trans-THC. As in the case of the THC scaffold, the cis-PET isomer is a less potent CB1R partial agonist than the trans-PET. Unexpectedly, the PET diastereoisomers differed pharmacologically from Δ9-trans-THC as it significantly reduced basal PGD2 and E2 levels in the brain in a CB1R-dependent manner, potentially limiting its adverse effects (20) and reducing neuroinflammation (19, 25). The interplay between CB1R activation by cannabinoids and modulation of PGE2 has been emphasized previously. Activation of CB1R by Δ9-trans-THC and CP55,940 was shown to induce COX-2 expression in different cell types, including neurons and astrocytes (20, 26, 27). Chen and colleagues (20) reported that Δ9-trans-THC acutely increases COX-2 expression in the brain in a CB1R-dependent mechanism by specifically recruiting a Gβγ subunit–mediated intracellular signaling, while 2-AG led to CB1R-dependent COX-2 suppression via the Gαi subunit. Moreover, in vivo, Δ9-trans-THC (10 mg/kg) strongly increased basal PGE2 levels in the hippocampal region, giving rise to central adverse effects (20). Using the same dose of Δ9-trans-THC, in our experiments we could not detect a significant change of basal PGD2 and PGE2 levels in mouse whole brain (Fig. 5, E and F). Conversely, PET diastereomers specifically reduced basal PGD2 and PGE2 levels without affecting COX-2 activity. It remains to be determined whether PET recruits the CB1R-mediated transduction pathways reported for 2-AG, which also reduces basal prostaglandin levels (19, 28). Recent studies have provided strong evidence that low-dose Δ9-trans-THC treatment may still be beneficial with reduced central side effects (29, 30). Thus, the less potent PET diastereoisomers showing additional effects on brain prostaglandin levels exhibit pharmacological characteristics of potential medical phytocannabinoids. The inhibition of constitutive prostaglandin production is not associated with toxic effects in the brain, while in the periphery, it may induce an impairment of the renal plasma flow, possibly leading to kidney injury (31–33). Although the moderate but significant inhibition of brain prostaglandin levels induced by cis-PET is not comparable to the pharmacological blockage of COX-2 activity elicited by nonsteroidal anti-inflammatory drugs, the reduction of brain prostaglandins may contribute to the neuropharmacology of this new cannabinoid (20). Our data also provide additional important information about the functional consequences of Δ9-THC side-chain modifications (34, 35). Using stereodivergent total synthesis, after more than 20 years from the first report of cis-PET, this study finally uncovers the underlying molecular mechanism of action. This gives a rationale for the recreational use of Radula liverworts and provides a molecular basis on which to assess the prospective toxicity and usefulness of the plant material.
Moreover, the findings on the pharmacological effects of cis-PET provide a marked example of convergent evolution of bioactive plant secondary metabolites in the plant kingdom. Despite the existence of more than 20,000 bryophyte species globally, cis-PET is the first psychoactive constituent in this group of plants. Recently, putative genes involved in the biosynthesis of cis-PET were described (8). The abuse potential of Radula species is probably low, given the relatively moderate potency and low abundance of cis-PET (0.7 to 7% in an extract) (5, 6) as compared with marijuana, with Δ9-trans-THC contents typically higher than 10% (36). Nevertheless, cis-PET could be an interesting lead for drug development as it might have fewer side effects than Δ9-trans-THC and reduces prostaglandins. The likely relevance of signaling-specific CB1R pathways (37), in particular related to the reduced prostaglandin biosynthesis observed with the bibenzyl PET scaffold, will need to be studied in preclinical disease models.
Unless otherwise noted, all reactions were carried out under an ambient atmosphere, and all reagents were purchased from commercial suppliers and used without further purification. The amine catalysts (S)-α,α-bis[3,5-bis(trifluoromethyl)phenyl]-2-pyrrolidinemethanol trimethylsilyl ether and (R)-α,α-bis[3,5-bis(trifluoromethyl)phenyl]-2-pyrrolidinemethanol trimethylsilyl ether were purchased from Sigma-Aldrich. The (R)-enantiomer was received as an off-white solid and was therefore purified by column chromatography before use to give a white solid. [Ir(cod)Cl]2 (97%) was purchased from Combi-Blocks Inc. Analytical thin-layer chromatography (TLC) was performed on Merck silica gel 60 F254 TLC glass plates and visualized with 254-nm light and potassium permanganate or Seebach’s “magic” staining solutions followed by heating. Purification of reaction products was carried out by flash chromatography using Sigma-Aldrich silica gel, 60 Å, 230 to 400 mesh under 0.3 to 0.5 bar pressure. The ligands (S)-L and achiral rac-L were prepared following known procedures (13, 38). Aldehyde 2 was prepared by published procedures (13, 39). 1H nuclear magnetic resonance (NMR) spectra were recorded on a Bruker AV 400-MHz spectrometer and are reported in parts per million (ppm), with the solvent resonance used as the internal standard (CHCl3 at 7.26 ppm). Peaks are reported as follows: s = singlet, d = doublet, t = triplet, q = quartet, or m = multiplet, coupling constant(s) in Hz, integration. 13C NMR spectra were recorded with 1H decoupling on a Bruker AV 101-MHz or Bruker AV 151-MHz spectrometer and are reported in parts per million, with the solvent resonance used as the internal standard (CDCl3 at 77.16 ppm). Peaks are reported as follows: s = singlet, d = doublet, coupling constant(s) in Hz. 19F NMR spectra were recorded with 1H decoupling on a Bruker AV 377-MHz or Bruker AV 471-MHz spectrometer and are reported in parts per million. Peaks are reported as follows: s = singlet, d = doublet, coupling constant(s) in Hz. Unless otherwise noted, all NMR measurements were conducted at room temperature. NMR service measurements were obtained at the NMR spectrometry service operated by the Laboratory of Organic Chemistry at the Eidgenössische Technische Hochschule Zürich (ETHZ). Infrared spectra were measured neat on a PerkinElmer UATR Two Spectrometer. The peaks are reported as absorption maxima (n, cm−1). High-resolution mass spectral data were obtained at the MS service operated by the Laboratory of Organic Chemistry at the ETHZ on a Micromass (Waters) AutoSpec Ultima–EI-Sector-MS (EI), Bruker maXis–ESI-Qq-TOF-MS (ESI), or Bruker solariX–MALDI-FTICR-MS (Dual MALDI/ESI) and are reported as mass/charge ratio (m/z). Enantiomeric excesses were determined on a Waters ACQUITY UltraPerformance Convergence Chromatography supercritical fluid chromatography (SFC) system using a chiral stationary phase DAICEL CHIRALCEL OJ-H (3 μm, 4.6 mm by 150 mm). Optical rotations were measured with a JASCO P-2000 Polarimeter (10 cm, 1-ml cell).
[3H]CP55,940 and [35S]GTPγS were obtained from PerkinElmer Life Sciences (Waltham, MA, USA). WIN55,212, AA (5Z,8Z,11Z,14Z-eicosatetraenoic acid), AA-d8 (5Z,8Z,11Z,14Z-eicosatetraenoic-5,6,8,9,11,12,14,15-d8 acid), AEA (N-(2-hydroxyethyl)-5Z,8Z,11Z,14Z-eicosatetraenamide), AEA-d4 [N-(2- hydroxyethyl-1,1,2,2-d4)-5Z,8Z,11Z,14Z-eicosatetraenamide], 2-AG (5Z,8Z,11Z,14Z-eicosatetraenoic acid, 2-glyceryl ester), 2-AG-d5 (5Z,8Z,11Z,14Z-eicosatetraenoic acid, 2-glyceryl-1,1,2,3,3-d5 ester), linoleoyl ethanolamide [LEA or N-(2-hydroxyethyl)-9Z,12Z-octadecadienamide], LEA-d4 [N-(2-hydroxyethyl-1,1,2,2-d4)-9Z,12Z-octadecadienamide], oleoyl ethanlonamide [OEA or N-(2-hydroxyethyl)-9Z-octadecenamide], OEA-d4 [N-(2-hydroxyethyl-1,1,2,2-d4)-9Z-octadecenamide], palmitoylethanolamide [PEA or N-(2-hydroxyethyl)-hexadecanamide], PEA-d5 [N-(2-hydroxyethyl)-hexadecanamide-15,15,16,16,16-d5], PGE2 (9-oxo-11α,15S-dihydroxy-prosta-5Z,13E-dien-1-oic acid), PGE2-d4 (9-oxo-11α,15S-dihydroxy-prosta-5Z,13E-dien-1-oic-3,3,4,4-d4 acid), PGD2 (9α,15S-dihydroxy-11-oxo-prosta-5Z,13E-dien-1-oic acid), progesterone (PROG or 4-pregnene-3,20-dione), PROG-d9 (progesterone-2,2,4,6,6,17α,21,21,21-d9), and corticosterone (11β,21-dihydroxy-pregn-4-ene-3,20-dione) were obtained from Cayman Chemicals Europe (Ann Arbor, MI, USA). Guanosine triphosphate (GTP) and guanosine diphosphate (GDP) were purchased from Sigma (St. Louis, Missouri, USA). Rimonabant (SR141716A, SR1) with a purity >98% was ordered from Pharmaserv AG, Switzerland. (−)-Δ9-cis-THC and (−)-Δ9-trans-THC were synthesized and prepared with a purity >95% as previously reported (see the Supplementary Materials for NMR spectra) (13).
The enzyme inhibition assays were performed as previously published (40). Briefly, for AEA and 2-OG hydrolysis, different concentrations of cis-PET, trans-PET, and Δ9-trans-THC were preincubated with 200 μg of pig brain homogenate in tris-HCl buffer (pH 7.6) supplemented with 0.1% of fatty acid–free BSA for 20 min at 37°C. Then, 0.1 μM AEA or 1 μM 2-OG containing trace amounts of [ethanolamine-1-3H]-AEA (1 nM) or [glycerol-1,2,3-3H]-2-OG (1 nM), respectively, were incubated with the mixtures for another 15 min at 37°C. The reaction was stopped by adding two volumes of ice-cold CHCl3:MetOH mixture (1:1) and centrifuged at 16,000g for 10 min at 4°C. The aqueous phase was collected, and the radioactivity was measured by liquid scintillation spectroscopy. hABHD6 and hABHD12 activity was determined using cell homogenates from hABHD6 and hABHD12 stably transfected human embryonic kidney (HEK) 293 cells. Different concentrations of cis-PET, trans-PET, and Δ9-trans-THC were preincubated with 40 μg of cell homogenate for 30 min at 37°C in assay buffer [1 mM tris, 10 mM EDTA, and 0.1% BSA (pH 7.6)]. Dimethyl sulfoxide (DMSO) was used as vehicle control, and 10 μM WWL70 or 20 μM tetrahydrolipstatin (THL) as positive controls. Then, 10 μM 2-OG was added and incubated for 5 min at 37°C. The reaction was stopped by the addition of 400 μl of ice-cold CHCl3:MeOH (1:1). The samples were vortexed and centrifuged (16,000g, 10 min, 4°C). Aliquots (200 μl) of the aqueous phase were assayed for tritium content by liquid scintillation spectroscopy. Blank values were recovered from tubes containing no enzyme. Basal 2-OG hydrolysis occurring in nontransfected HEK293 cells was subtracted. Inhibition of human recombinant COX-2 was assessed using an in-house validated COX fluorescent inhibitor screening assay kit from Cayman Chemical Europe as previously described (40).
cis-PET and Δ9-trans-THC were profiled in a Cerep (Eurofins Pharma Discovery Services) screening panel of 44 targets including GPCRs, ion channels, nuclear receptors, membrane transporters, and enzymes mostly expressed in the CNS. cis-PET was tested at 1 and 10 μM, while Δ9-trans-THC was tested only at 1 μM. Data presented were obtained from two independent experiments each performed in duplicate. The GPCRs tested were as follows: α1A adrenergic receptor, α2A adrenergic receptor, α2B adrenergic receptor, β1 adrenergic receptor, β2 adrenergic receptor, CB1R, CB2R, D1 dopamine receptor type 1, D2 dopamine receptor type 2, H1 histamine receptor type 1, H2 histamine receptor type 2, delta-type opioid receptor, mu-type opioid receptor, kappa-type opioid receptor, 5-HT1A serotonin receptor, 5-HT1B serotonin receptor, 5-HT2A serotonin receptor, 5-HT2B serotonin receptor, 5-HT3 serotonin receptor, M1 muscarinic receptor, M2 muscarinic receptor, M3 muscarinic receptor, A2A adenosine receptor, ETA endothelin receptor, CCK1 cholecystokinin A receptor, and V1A vasopressin/oxytocin receptor. Ion channels were as follows: GABAA channel at the benzodiazepine (BZD), α4/β2 acetylcholine ion channel, Cav1.2 (l-type) calcium ion channel (dihydropyridine site), Kv voltage-gated potassium ion channel, Na+ voltage-gated sodium channel, human ether-a-go-go-related gene (hERG) potassium channels, N-methyl-d-aspartate (glutamate) receptor. Nuclear receptors were as follows: androgen receptor and glucocorticoid receptor. Enzymes were as follows: MAO-A, acetylcholinesterase, lymphocyte-specific protein tyrosine kinase phosphodiesterase 3A, phosphodiesterase 4D2, COX-1, and COX-2. Membrane neurotransmitter transporters were as follows: noradrenaline transporter, DAT, and serotonin transporter.
Compounds were dissolved in pure DMSO and administered intraperitoneally at different doses using five to eight mice for each treatment group. cis-PET, trans-PET, and Δ9-trans-THC were administered 1 hour before assessing locomotion, catalepsy, body temperature, and analgesia (collectively referred as tetrad test). The rectal temperature was measured before (basal) and 1 hour after injection with a thermocouple probe (1 to 2 cm; Testo AG, Switzerland), and the change in rectal temperature was expressed as the difference between basal and postinjection temperatures. Catalepsy was measured using the bar test, where mice were retained in an imposed position with forelimbs resting on a bar 4 cm high; the end point of catalepsy was considered when both front limbs were removed or remained over 120 s. Locomotion was determined using the rotarod test; animals were placed on the rotarod (Ugo Basile, Italy) at 6 rpm, and the latency to fall was measured with a cutoff time of 120 s. Catalepsy and locomotion were measured in three trials. The hot plate test was performed to evaluate analgesia using a 54° to 56°C hot plate (Thermo Scientific, Waltham, Massachusetts, USA) with a Plexiglas cylinder. The latency to the first nociceptive response (paw lick or foot shake) was measured.
LC-MS/MS quantifications of PET, THC, AEA, 2-AG, PEA, LEA, OEA, AA, PGD2, and PGE2 in mouse brain tissue. LC-MS/MS analyses were performed on a Shimadzu UFLC coupled to a TripleQuad 4000 QTRAP mass spectrometer (ABSciex Concord, Ontario, Canada). AEA, 2-AG, OEA, PEA, LEA, AA, PGE2, and PGD2 were quantified in mouse brains using our recently published method (40). For the analysis of cis-PET, trans-PET, and Δ9-trans-THC, a Reprosil Fluosil 100 PFP (particle size, 3 μm; 2 mm by 50 mm; Dr. A. Maisch, Germany) column was used in reversed-phase mode with gradient elution starting with 95% of phase A (0.1% formic acid and 2 mM ammonium acetate in water) and 5% of phase B (0.1% formic acid in acetonitrile). The amount of phase B was linearly increased to 40% at 3 min, then to 58% at 8 min and kept for 1 min, and then increased linearly again to 80% at 10 min; the column was flushed for 3.5 min with 99% of phase B with subsequent reequilibration at 5% for a further 3 min. The total analysis time was 17 min at 40°C, the flow rate was 0.3 ml/min, and the injection volume was 10 μl. These LC conditions provided the chromatographic resolution of cis- and trans-PET prior to MS/MS (see fig. S6 for the chromatogram), where both isomers ([M+H+] of 349 m/z) showed the same fragmentation pattern (m/z = 293, 267, 227). The TurboIon Spray interface was operated in positive mode. The MS parameters of the ESI source were as follows: capillary voltage, 4.5 kV; temperature, 600°C; nebulizer pressure, 50 psi. Peaks were integrated using the Analyst software version 1.5 (AB Sciex Concord, Ontario, Canada). Because of the lack of a deuterated version for interested molecules and the chemical similarity between Δ9-trans-THC and both PET isomers, we used Δ9-trans-THC as internal standard (IS) for cis- and trans-PET, whereas cis-PET was used as IS for Δ9-trans-THC. The ratio of peak area of analyte to peak area of IS was used to ensure linearity of the calibrations. The slope, intercept, and regression coefficient of those calibration lines were determined. The concentrations of PET diastereosimoners and Δ9-trans-THC in the brain and plasma were calculated applying a model previously described (40). The ratios between brain and plasma concentrations (Kp) of Δ9-trans-THC, cis-PET, and trans-PET were calculated as previously reported (40).
Mouse brains were divided into two sagittal hemispheres, and one hemisphere was used for LC-MS/MS analyses. Half brains were weighted when still frozen and transferred to 2-ml microcentrifuge vials (XXTuff Microvials, BioSpec, Oklahoma, USA) with three chrome-steel beads (diameter, 2.3 mm; BioSpec, Oklahoma, USA) and 1.5 ml of 0.1 M formic acid. Samples were homogenized using a 24-position Mini bead beater (BioSpec Products Inc., Bartlesville, OK, USA) for the extraction of administered molecules (cis-PET, trans-PET, and Δ9-trans-THC), as well as for endogenous molecules AEA, 2-AG, PEA, OEA, LEA, PGE2, PGD2, AA, corticosterone, and progesterone using a previously described extraction protocol (40). For the quantification of cis-PET, trans-PET, and Δ9-trans-THC, a different extraction method was used. Briefly, 200 μl of brain homogenate or plasma was rapidly transferred to a silanized Eppendorf tube containing 400 μl of acetone and 400 ng/ml of the designed internal standard. Samples were centrifuged at 13,200 rpm for 10 min at 4°C to precipitate proteins, and the supernatant was further extracted with 1 ml of ethyl acetate:hexane (9:1) 0.1% formic acid strongly vortexed for 30 s and sonicated (Sonicator Merck-Gruppe) in a cold bath for 5 min. Samples were centrifuged at 13,200 rpm for 10 min at 4°C and kept for 1 hour at −20°C to freeze the lower aqueous phase. The upper organic phase was recovered in plastic tubes and dried into a speed vacuum. The extracts were reconstituted in 50 μl of acetonitrile with 20% of water, and 10 μl was injected in the LC-MS/MS system.